Recce Pharmaceuticals Ltd. · ASX:RCE
Recce Pharmaceuticals — Shareholder Meeting (November 2016)
18 slides from Recce Pharmaceuticals's shareholder meeting presentation, Nov 22, 2016

Slide 1: AGM Presentation
AGM Presentation 22 November 2016 Presented by Dr Graham Melrose (Executive Chairman) Recce Ltd© ASX: RCE 1

Slide 2: Disclaimer
Disclaimer ALL CURRENCY AMOUNTS ARE IN AUD UNLESS STATED OTHERWISE. DISCLAIMER This presentation has been prepared by Recce Ltd (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You

Slide 3: Corporate and investment summary
Corporate and investment summary Overuse of antibiotics has led to antibiotic resistant bacteria. Antibiotic resistant bacteria or superbugs have become a major world health issue. Recce is focused on developing a new class of synthetic anti-bacterials with a broad spectrum of activity against antib

Slide 4: Recce synthetic antibiotics
Recce synthetic antibiotics • Recce has synthesized and patented a new class of antibiotics. • These new compounds have demonstrated safety and efficacy in a range of pre-clinical tests to kill a number of common antibiotic resistant bacteria. • Recce’s new synthetic antibiotic compounds show positi

Slide 5: Lead RECCE compound
Lead RECCE® 327 compound RECCE® 327 is our lead synthetic antibiotic candidate in pre-clinical development Extensive pre-clinical studies have demonstrated positive in-vitro (in the lab) and in-vivo (in animals) to date: • Demonstrates anti-infective properties against S. aureus and E. coli. • Impor

Slide 6: RECCE antibiotics: Sepsis
RECCE® antibiotics Sepsis • “Sepsis affects over 26 million people worldwide each year - one third die” • “It is the largest killer of children and new-born infants in the world” • “Sepsis is increasing at an annual rate of 8-13%” • “In the United States, sepsis kills more people than colon cancer,

Slide 7: Technology: Very resistant – P. aeruginosa (Gr-ve superbug)
Technology: Very resistant – P. aeruginosa (Gr-ve superbug) Pre-infection Full infection After 1 hour treatment with RECCE® 327 Complete kill 7

Slide 8: RECCE kills at practical speeds
RECCE® 327 kills at practical speeds* Rates of kill of standard bacteria S. aureus E. coli P. aeruginosa S. pyogenes C. difficile 20 – 60 20 – 60 1 – 24 20 – 60 20 – 60 minutes minutes hours minutes minutes Rates of kill of Superbugs S. aureus E. coli P. aeruginosa The same kill-rates for standard b

Slide 9: RECCE does not Fail
RECCE® 327 does not Fail Number of repetitive uses before displaying loss of antibiotic activity S. aureus E. coli P. aeruginosa Commercial Commercial Commercial antibiotic antibiotic antibiotic 8 4 10 RECCE® Antibiotic >25 After repetitive use, the commercial antibiotic loses activity; RECCE® 327 D

Slide 10: Technology – How it works
Technology – How it works RECCE® antibiotics attack protein in the cell wall of bacteria – outward pressure in the bacteria, causes only them to rupture. 10

Slide 11: Technology – How it works
Technology — How it works Recce 3 RECCE® 327 Bacteria bursts @ 4 RECCE® 327 Redundant bacteria are absorbed @ RECCE® 327 @ BACTERIUM oe d : ‘ouTwaRD PRESSURE eve uu

Slide 12: Natural vs Synthetic
Natural vs Synthetic • Commercial antibiotics are naturally derived – superbugs to them have been forming for millenniums – and will continue to do so • RECCE® 327 is wholly synthetic – superbugs never formed in nature – designed for a purpose! 12

Slide 13: Expected news flow next 12 months (calendar year)
Expected news flow next 12 months (calendar year) 2016 2017 Additional RECCE® 327 safety and efficacy data Final toxicology and efficacy test data Oral dosing toxicology and efficacy data in mice Rat pharmacokinetic results Anti-viral efficacy results in mice Dog pharmacokinetic results Anti-cancer

Slide 14: Recce business model – strategy to create long-term value
Recce business model – strategy to create long-term value Pharma & biotech partnerships New class of Revenues, upfronts, synthetic milestones, royalties Recce synthetic antibiotics antibiotic platform Potential in multiple In-house disease indications Licensing of pipeline of drug distribution candi

Slide 15: Board and management in place to deliver
Board and management in place to deliver Dr Graham Melrose: Executive Chairman Peter Williams: CFO and Company Secretary Accomplished senior ASX finance professional with significant Founder and inventor. Former Chief Research Executive of local and international experience. Former VP Finance with J

Slide 16: A supportive legislative and financial landscape globally for new antibiotics
A supportive legislative and financial landscape globally for new antibiotics The global need for new antibiotics is urgent and a major economic and social issue. The rapid development of new antibiotics is supported by a range of initiatives by governments and private investors globally. Legislatio

Slide 17: Supportive legislative and financial landscape
Supportive legislative and financial landscape Economics: • Former UK Prime Minister David Cameron commissioned a report analysing the economic and social costs of the problem and propose concrete actions to tackle it internationally. • The O’Neil Review on Antimicrobial Resistance published in 2015

Slide 18: RECCE – a Technology
RECCE® 327 – a Technology Compared to the risk of a single opportunity from a one-use product - Recce’s technology enjoys the added security of multiple product opportunities. 18
Source: Internet Archive copy of recce.com.au
More decks from Recce Pharmaceuticals Ltd.
Shareholder Meeting (November 2026)19 slides · Nov 6, 2026
Investor Presentation (November 2026)45 slides · November 2026
Investor Presentation (October 2026)42 slides · October 2026
Shareholder Meeting (September 2026)10 slides · Sep 2, 2026
Investor Presentation (September 2026)42 slides · September 2026
Investor Presentation (August 2026)40 slides · August 2026